Pleiotropic Effects of 3-O-Decanoylquercetin on U373-MG Human Glioma Cell Line

Paola Dell'Albani1, Valentina La Cognata1, Sebastiano Alfio Torrisi2

  • 1Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), Via P. Gaifami, 18, 95126 Catania, Italy.

Insights

A quercetin derivative, Q-3-Dec, shows promise against brain tumors called gliomas. It targets multiple cancer survival pathways and DNA repair mechanisms, leading to increased glioma cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Gliomas are aggressive brain tumors with complex signaling pathways driving growth and treatment resistance.
  • Quercetin, a natural flavonoid, has anticancer properties, leading to the development of enhanced derivatives like Q-3-Dec.
  • O6-Methylguanine-DNA Methyltransferase (MGMT) is a DNA repair enzyme linked to glioma chemoresistance.

Purpose of the Study:

  • To investigate the multi-target effects of 3-O-decanoylquercetin (Q-3-Dec) on glioma cells.
  • To assess Q-3-Dec's impact on survival signaling, mitochondrial function, and MGMT expression in gliomas.
  • To evaluate Q-3-Dec's potential as a therapeutic agent for glioma.

Main Methods:

  • Treatment of U373-MG glioma cells with Q-3-Dec.
  • Assessment of morphological changes and mitochondrial membrane potential.
  • Analysis of NF-κB and STAT3 phosphorylation, Bcl-2, survivin, and MGMT expression.
  • Quantification of cell death over 48 hours.

Main Results:

  • Q-3-Dec induced significant morphological changes and mitochondrial dysfunction in glioma cells.
  • Treatment reduced NF-κB and STAT3 signaling, and decreased levels of anti-apoptotic proteins (Bcl-2, survivin) and MGMT.
  • A progressive increase in glioma cell death, reaching approximately 30% at 48 hours, was observed.

Conclusions:

  • Q-3-Dec acts as a multi-node modulator of glioma cell survival.
  • The compound effectively targets key pathways involved in glioma growth and chemoresistance.
  • Q-3-Dec demonstrates potential for further preclinical development in glioma therapy.

Related Concept Videos